COMMUNIQUÉS West-GlobeNewswire

Women in Science: Breaking Barriers with HNL Lab Medicine
31/01/2025
ALLENTOWN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Women are still vastly underrepresented in science, technology, engineering, and math (STEM) fields, with only 18% of women holding STEM jobs in the United States, [...]
EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation
31/01/2025
Full-Year 2024 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation
31/01/2025
Full-Year 2024 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr [...]
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
31/01/2025
Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., Jan. 31, 2025 ( [...]
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
31/01/2025
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow. 1 These patients may now be eligible for a [...]
Correction: GUERBET : Financial agenda for 2025
31/01/2025
CORRECTION - Financial agenda for 2025 Villepinte, 13 janvier 2025 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. [...]
Correction: GUERBET : Calendrier financier de l'exercice 2025
31/01/2025
RECTIFICATIF - Calendrier financier de l’exercice 2025 Villepinte, le 13 janvier 2025 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son [...]
Heron’s Key Announces Exciting Expansion with Upcoming Pre-Sales
31/01/2025
GIG HARBOR, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Heron’s Key , a premier Life Plan Community member of Emerald Communities, is thrilled to announce the highly anticipated expansion of our community, with pre-sales [...]
TerrAscend Announces Preliminary Fourth Quarter 2024 Financial Results and Schedules Earnings Conference Call
31/01/2025
Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024 Gross Profit Margin of 50.2%, an increase of 140 basis points quarter-over quarter Generated Positive Cashflow from Operations in the [...]
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
31/01/2025
Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic global expansion [...]
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
31/01/2025
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, [...]
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
31/01/2025
US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025. Accordingly, any shares of the [...]
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
31/01/2025
● Q4 and FY Test volume increase 21% and 17% year-over-year ● Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“ [...]
ARCPOINT ANNOUNCES C$800,000 NON-BROKERED PRIVATE PLACEMENT
31/01/2025
For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire Services Greenville, South Carolina, Jan. 31, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint [...]
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
31/01/2025
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the [...]
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
31/01/2025
Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 [...]
NewGen Announces Reverse Stock Split
31/01/2025
NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025 BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive [...]
Retrieve Medical Expands into Ambulatory Care with New Client Engagement
31/01/2025
BEDMINSTER, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Retrieve Medical, Inc. ( www.retrievemedical.com ) announces its expansion into the ambulatory care sector through a new client engagement with Saint Joseph’s Medical [...]
Immutep Quarterly Activities Report Q2 FY25
31/01/2025
Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT- [...]

Pages